Treatment guidelines for HIV-associated wasting

HIV Clinical Trials

Volumn 5, Issue 1, 2004, Pages 50-61

  Polsky, Bruce ^a   Kotler, Donald ^b   Steinhart, Corklin ^c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Mercy Hospital ^*  (United States)

^c Mercy Hospital Miami   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; APPETITE STIMULANT; HUMAN GROWTH HORMONE; MEGESTROL ACETATE; NANDROLONE DECANOATE; OXANDROLONE; PENTOXIFYLLINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TESTOSTERONE; THALIDOMIDE; VITAMIN;

ACNE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANDROGEN THERAPY; ANOREXIA; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; CACHEXIA; CANCER GROWTH; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDEMA; HAIR LOSS; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPOGONADISM; IMPEDANCE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIPOHYPERTROPHY; LIVER TOXICITY; MORBIDITY; MORTALITY; MYALGIA; OSTEOPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE DISEASE; SKIN MANIFESTATION; SLEEP APNEA SYNDROME; WASTING SYNDROME; WEIGHT GAIN;

ANABOLIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; FEMALE; HIV INFECTIONS; HIV WASTING SYNDROME; HUMANS; MALE; NANDROLONE; NUTRITIONAL STATUS; OXANDROLONE;

EID: 1642312148     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/6LAR-CPWA-XEH9-WG3T     Document Type: Article

References (63)

1. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr. 1985;42:1255-1265.
2. Ott M, Lembcke B, Fischer H, et al. Early changes in body composition in human immunodeficiency virus-infected patients: Tetrapolar body impedance analysis indicates significant malnutrition. Am J Clin Nutr. 1993;57:15-19.
3. Council of State and Territorial Epidemiologists, AIDS Program, Center for Infectious Diseases. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1987; 36(suppl1):1S-15S.
4. Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cell mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50:444-447.
5. Chlebowski RT, Grosvenor MB, Bernhard NH, et al. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol. 1989;84:1288-1293.
6. Guenter P, Muurahainen N, Simons G, at al. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr. 1993;6:1130-1138.
7. Palenicek JP, Graham NM, He YD, at al. Multicenter AIDS Cohort Study Investigators. Weight loss prior to clinical AIDS as a predictor of survival. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:366-373.
8. Cohan GR, Muurahainen N, Guenter P, et al. HIV-related hospitalizations, CD4 percent and nutritional markers. Program and abstracts of the Eighth International Conference on AIDS; July 19-24,1992. Abstract Pu.B.7113.
9. Turner J, Muurahainen N, Terrell C, et al. Nutritional status and quality of life. Program and abstracts of the X International Conference on AIDS, Tokyo, Japan; Aug 7-12, 1994. Abstract 431B.
10. Wheeler DA, Muurahainen N, Elion R, et al. Change in body weight (WT) as a predictor of death and opportunistic complications (OC) in HIV by history of prior OC. Program and abstracts of the XI International Conference on AIDS, Vancouver, British Columbia; July 7-12, 1996. Abstract Tu.B.2383.
11. Carr A, Samaras K, Burton S, at al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-58.
12. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS. 1998;12:1645-1651.
13. Lo JC, Mulligan K,Tai VW, et al. 'Buffalo hump' in men with HIV-1 infection. Lancet. 1998;351:867-870.
14. Torres RA. Treatment of dorsocervical fat pads and truncal adiposity with Serostim (recombinant human growth hormone) in patients with AIDS maintained on HAART. Program and abstracts of the 12th World AIDS Conference, Geneva, Switzerland; June 28-July 3, 1998. Abstract 32164.
15. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871-875.
16. Engelson ES, Kotler DP, Tan Y, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr. 1999;69:1162-1169.
17. Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;31:803-805.
18. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15;43-48.
19. Berger D, Cimoch P, Nemechek P, et al. Measurement of body weight and body cell mass in patients receiving highly active antiretroviral therapy (HAART). Program and abstracts of the 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario; September 28-October 1, 1997.
20. Schwenk A, Beisenherz A, Romer K, et al. Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment. Am J Clin Nutr. 2000;72:496-501.
21. Mocroft A, Sabin CA, Youle M, et al. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. J Acquir Immune Defic Syndr. 1999;21:401-407.
22. Nemechek PM, Polsky B, Gottlieb M. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc. 2000;75:386-394.
23. Teixeira A, Leu JC, Honderlick P, et al. Variation in body weight and plasma viral load in HIV patients treated with tritherapy including a protease inhibitor [abstract]. Nutrition. 1997;13:269.
24. Zuchman D, Teixeira A, Olivieri M, et al. Correlation between body composition, caloric intake and plasma viral load in HIV infected patients [abstract]. Nutrition. 1997;13:292.
25. Muurahainen N, et al. Detection of occult wasting by BIA technology. Program and abstracts of the X International Conference on AIDS, Tokyo, Japan; August 7-12, 1994. Abstract PB0895.
26. Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev. 1991;49:163-175.
27. National Institutes of Health. Bioelectrical impedance analysis in body composition measurement. National Institutes of Health Technology Assessment Conference Statement. December 12-14, 1994, Am J Clin Nutr. 1996;64(suppl):524S-532S.
28. Grinspoon S, Cocoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 1997;82:1332-1337. [Erratum, J Clin Endocrinol Metab. 1997;82:3360.]
29. Wachtel T, Piette J, Mor V, et al. Quality of life in persons with human immunodeficiency virus infection: Measurement by the Medical Outcomes Study instrument. Ann Intern Med. 1992;116:129-137.
30. Stanton DL, Wu AW, Moor RD, et al. Functional status of persons with HIV infection in an ambulatory setting. J Acquir Immune Defic Syndr. 1994;7:1050-1056.
31. Nerad JL, Gorbach SL. Nutritional aspects of HIV infection. Infect Dis Clin North Am. 1994;8:499-515.
32. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89-97.
33. Timpone JG, Wright DL, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses. 1997;13:305-315.
34. Von Roenn JH, Armstrong D, Kotler DP, et al. Megesterol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994;121:393-399.
35. Oster MH, Enders SR, Samuels SJ, et al. Megesterol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400-408.
36. Summerbell CD, Youle M, et al. Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. Int J STD AIDS. 1992;3:278-280.
37. Bhasin S, Storer TW, Asbel-Sethl N, at al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab. 1998;83:3155-3162.
38. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129:18-26.
39. Grinspoon S, Corocoran C, Anderson E, et al. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis. 1999;28:634-636.
40. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss. AIDS. 1997;11:1347-1352.
41. Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med. 2000;133:348-355.
42. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: A randomized, placebo controlled trial. Ann Intern Med. 1996;125:873-882.
43. Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;125:865-872.
44. Dear E, Gaccione P, Muurahainen N, et al. Gains in lean body mass (LBM) and not body fat are associated with improved survival in patients with AIDS wasting (AW). Program and abstracts of the 5th International Congress on Drug Therapy in HIV Infection, Glasgow, UK; October 22-26, 2000. Abstract 339.
45. Gold J, High HA, Li Y, et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS. 1996;10:745-752.
46. Bucher G, Berger DS, Fields-Gardner C, Jones R, Reiter WM. A prospective study on the safety and effect of nandrolone decanoate in HIV-positive patients. Program and abstracts of the XI International Conference on AIDS, Vancouver, British Columbia; July 7-12, 1996. Abstract MoB423.
47. Strawford A, Barbieri T, Neese R, et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:137-146.
48. Poles MA, Meller JA, Linn A, Weiss WR, et al. Oxandrolone as a treatment for AIDS-related weight loss and wasting. Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997. Abstract 695.
49. Romeyn M, Gunn N 3rd. Resistance exercise and oxandrolone for men with HIV-related weight loss. JAMA. 2000;284:176.
50. Sinha-Hikim I, Arver S, Beall G, et al. The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1998;83:1312-1318.
51. Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency wasting: A pilot study. J Clin Endocrinol Metab. 1998;83:2717-2725.
52. Forbes GB. Lean body mass-body fat interrelationships in humans. Nutr Rev. 1987;45:225-231.
53. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA. 2000;283:763-770.
54. Spence DW, Galantino ML, Mossberg KA, et al. Progressive resistance exercise effect on muscle function and anthropometry of a select AIDS population. Arch Phys Med Rehabil. 1990;71:644-648.
55. Roubenoff R, McDermott A, Wood M, et al. Feasibility of increasing lean body mass in HIV-infected adults using progressive resistance training. Program and abstracts of the 12th World AIDS Conference, Geneva, Switzerland; June 28-July 3, 1998. Abstract 42357.
56. Rigsby LW, Dishman RK, Jackson AW, et al. Effects of exercise training on men seropositive for human immunodeficiency virus-1. Med Sci Sports Exerc. 1992;24:6-12.
57. Kotler DP, Tierney AR, Ferrarao R, et al. Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr. 1991;53:149-154.
58. Melchlor J, Chasstang C, Gelas P. Efficacy of 2-month total parenteral nutrition in AIDS patients: A controlled randomized prospective trial. AIDS. 1996;10:379-384.
59. Kotler DP, Tierney AR, Culpepper-Morgan JA, et al. Effects of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr. 1990;14:454-458.
60. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327:329-337.
61. Haslett P, Hempstead M, Seidman C, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses. 1997;13:1047-1054.
62. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996;10:1501-1507.
63. Kaplan G. Thomas S. Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS. 2000;16: 1345-1355.